Hong Kong-listed Chinese biotech firm Jacobio Pharma says it hopes to commercialize a new drug that it's developing with AstraZeneca (AZN). Speaking on Bloomberg's "The China Show," the company's Co-CEO, Chief Medical Officer and Global Head of R&D Andrea Wang-Gillam discusses the significance of the Pan-KRAS inhibitor and her company's business outlook.

Bloomberg videos, provided by MT Newswires